Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 52862

Drug Profile

E 52862

Alternative Names: E-52862; E-52862.HCl; MR-309; S1A; S1RA

Latest Information Update: 20 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Esteve
  • Developer ESTEVE
  • Class Non-opioid analgesics
  • Mechanism of Action Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia; Postoperative pain
  • Preclinical Osteoarthritis

Most Recent Events

  • 28 Nov 2016 Efficacy and adverse event data from a phase II trial in Post-operative pain presented at the 16th World Congress on Pain (WCP-2016)
  • 28 Nov 2016 Esteve completes enrolment in the phase II trial for Post-Operative Pain in Spain
  • 26 Sep 2016 Efficacy and adverse events data from a phase II trial in Post-surgical neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top